Intestine targeted formulation of PEGylated rotavirus and its synthesizing method

Abstract

The present invention discloses polyglycol treated rotavirus antibody intestine targeting preparation as one kind of antibody medicine and its synthesis process. The novel medicine preparation is prepared through the following steps: first synthesizing the polyglycol activated intermediate MePEG-S-NHS and MePEG-S-EDC; then purifying specific anti-rotavirus antibody RV-IgY; and final performing structural modification of the specific anti-rotavirus antibody with the polyglycol activated intermediate MePEG-S-NHS and MePEG-S-EDC to prepare the polyglycol treated rotavirus antibody intestine targeting preparation. The medicine has certain intestine targeting and positioning effect, raised bioavailability, reduced toxic side effect of original medicine, certain delayed function and enhanced clinical treating effect. The medicine has obvious effect on infantile diarrhea caused by rotavirus.

Description

technical field [0001] The invention relates to a novel antibody drug and a preparation method thereof, in particular to a pegylated rotavirus antibody intestinal targeting preparation and a synthesis method thereof. Background technique [0002] In my country, there are 250 million children with diarrhea under the age of 5 every year, of which 120 million are autumn and winter diarrhea caused by rotavirus. Currently, there is no special treatment for this disease except oral or intravenous rehydration to correct dehydration. therapy. Rotavirus is highly contagious, and is often firstly infected by infants with weak resistance, and then spread to other children. Kindergartens are prone to spread infection and have a higher probability of nosocomial infection. After children are infected with rotavirus, due to frequent diarrhea and vomiting, loss of appetite, they are prone to dehydration in varying degrees, and electrolyte imbalance. What's more, encephalitis, intestinal ble...

AI Technical Summary

Problems solved by technology

Although anti-rotavirus-specific polyclonal antibody (RV-IgY) is used for the treatment of rotavirus diarrhea at present, unmodified naked antibody (RV-IgY) is the same as other antibodies or protein drugs, and is used in drug application. There are many shortcomings and limitations in the dosage form: 1) It is easy to cause the body's immune response; 2) It is easily degraded by various hydrolytic enzymes in the gastrointestinal tract; 3) The half-life is short and the bioavailability is low; 4) It is not easy to store, etc., so its curative effect greatly affected

[0005] At present, there are no relevant research reports on PEG-modified rotavirus antibody drugs at home and abroad The application and promotion in our country will drive the development of related industries

Images